The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C. A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C. A polymorphism and cancer, we found Bcl-2 -938 C. A polymorphism was significantly associated with increased cancer risk in dominant model (OR=1.12, 95% CI: 1.00-1.25, P=0.04), recessive model (OR=1.38, 95% CI: 1.11-1.71, P=0.004), allelic model (OR=1.15, 95% CI: 1.04-1.28, P=0.007) and homozygote comparison(OR=1.44, 95% CI: 1.11-1.87, P=0.006). Furthermore, Bcl-2 -938 C. A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C. A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR=0.99, 95% CI: 0.77-1.27, P=0.93; AA vs CC: OR=0.92, 95% CI: 0.65-1.30, P=0.63; AC vs CC: OR=0.94, 95% CI: 0.80-1.11, P=0.48; CC vs AA1CA: OR=1.21, 95% CI: 0.69-2.13, P=0.50; AA vs CC+CA: OR=0.99, 95% CI: 0.48-2.04, P=0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.
[1]Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China.
[2]Fudan Univ, Zhongshan Hosp, Dept Clin Lab Med, Shanghai 200032, Peoples R China.
[3]Tongji Univ, Shanghai Peoples Hosp 10, Dept Cent Lab, Shanghai 200072, Peoples R China.
(8.0+极速模式)